New shot aims to strengthen muscles in rare genetic disease

NCT ID NCT07531251

First seen Apr 24, 2026 · Last updated May 05, 2026 · Updated 4 times

Summary

This study tests a daily injection called elamipretide in 48 people with genetically confirmed Barth syndrome, a rare genetic condition that causes muscle weakness and heart problems. The goal is to see if the drug improves muscle strength and mobility over 72 weeks compared to a placebo. Participants will receive either the drug or a placebo injection daily, and their ability to walk, stand up, and move will be measured.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BARTH SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Bristol Royal Hospital for Children Upper Maudlin Street Paul O'Gorman Building

    Bristol, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Trial Not Offered in the U.S

    Needham, Massachusetts, 02494, United States

Conditions

Explore the condition pages connected to this study.